With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Shares of MeiraGTx Holdings (NASDAQ:MGTX) traded higher in the premarket on Thursday after the company, with its Q4 2024 results, announced an agreement with AI-focused research firm Hologen Limited ...

Holdings announced a broad strategic collaboration with Hologen. MeiraGTx will receive $200 million in upfront cash at closing ...

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

MeiraGTx Holdings shares rose 13% in premarket trading on a collaboration with Hologen that will bring in a cash infusion and create a joint venture. Shares were trading around $7.28. The stock is up ...

Reports FY24 revenue $33.279M vs $14.017M last year. “MeiraGTx (MGTX) demonstrated excellent execution in 2024, marked by significant ...

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

Investing.com -- Shares of MeiraGTx Holdings plc (Nasdaq: NASDAQ: MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...